Peer Review History

Original SubmissionApril 4, 2024
Decision Letter - Shahriar Ahmed, Editor

PONE-D-24-12276Laboratory validation of a simplified DNA extraction protocol followed by a portable qPCR detection of M. tuberculosis DNA suitable for point of care settings.PLOS ONE

Dear Dr. Costa,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

Thank you for submitting your well written manuscript to this journal. We believe that the comments from the reviewers are very constructive, should be fairly easy to respond to, and will improve the overall impact of the manuscript. We look forward to receiving the revised manuscript soon.

==============================

Please submit your revised manuscript by Aug 03 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Shahriar Ahmed, MBBS, MHE, MPhil

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. 

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

3. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript. 

4. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments:

Thank you for submitting your well written manuscript to this journal. We believe that the comments from the reviewers are very constructive, should be fairly easy to respond to, and will improve the overall impact of the manuscript. We look forward to receiving the revised manuscript soon.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: In the introduction

Please update data in the introduction (2021, 2022) with last up to date data if available.

Smear microscopy has low sensitivity but quite good specificity.

Real time PCR section

Explain why IS6110 region was selected to detect MTB.

You are using the Xpert Ultra cartridge. It is important to specify that from the beginning of the paper, and outlining its main difference with the regular MTB/Rif cartridge in terms of specificity and sensitivity

In the discussion.

It would be interesting to give a rough idea of how it would cost to test one individual when using the FTA + Q3-Plus. Obviously not doing a deep cost-effectiveness analysis but show how many individuals can be tested under routine practice by Xpert compared to FTA + Q3-plus.

I would recommend address more in details the trace results and elaborate more on the comparison/correlation of trace results vs FTA + Q3 plus.

In remote areas, it is usually the case that the level of competency of laboratory technicians is more limited. I suggest to mention how feasible it would be to implement this technology especially around the results interpretation, is there any language barrier to read the results,.

Please elaborate on the easiness for operating and what it really means for the laboratory technician if s/he were to use this technology. You mention it takes up to 4 hours using Q3-plus. I guess you are also including the extraction steps in those 4 hours, please specify in your text. Also please add details on how long the lab technician needs to have hands-on for samples handling and processing. For example for GeneXpert it could around 20 minutes hands-on (adding buffer, mixing for 10 + 5 minutes, load the sample in the cartridge, launch the test). Please indicate out of the 4 hours, how long is required for actual hands-on.

Please add some details on what it implies for the health system to end up with false negative and/or false positive results.

Please elaborate on the testing capacity of Xpert vs FTA+Q3-plus. How many samples can be tested in one run of 4 hours?

Reviewer #2: Current manuscript has described laboratory validation of a simplified DNA extraction protocol as a POC. Few issues that need to be discussed in the manuscript.

1. How affordable the assay will be as POC?

2. Have you compared the sensitivity, specificity of the children's specimens? Do you think this can be different?

3. Why only adults specimens had been chosen?

Thank you.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Reviewer #1

In the introduction

1. Please update data in the introduction (2021, 2022) with last up to date data if available.

Reply: Data in the introduction section was updated. (lines 29,30 and 31)

2. Smear microscopy has low sensitivity but quite good specificity.

Reply: The information is clarified (lines 33,34,35,36 and 37).

3. Explain why IS6110 region was selected to detect MTB.

Reply: The IS6110 was selected because it is a specific marker of the MTB complex (20, 21)and it used in several commercial diagnostic tests for tuberculosis. The explanation is stated in lines 151, 152, 153 and 154.

4. You are using the Xpert Ultra cartridge. It is important to specify that from the beginning of the paper, and outlining its main difference with the regular MTB/Rif cartridge in terms of specificity and sensitivity

Reply: We have specified all instances where Xpert Ultra was used. We also outlined the differences between the regular MTB/RIF and Ultra cartridges (lines 46-54).

In the discussion.

5. It would be interesting to give a rough idea of how it would cost to test one individual when using the FTA + Q3-Plus. Obviously not doing a deep cost-effectiveness analysis but show how many individuals can be tested under routine practice by Xpert compared to FTA + Q3-plus.

Reply: Although the GeneXpert Ultra assay showed better results and a faster turnaround time of 80–90 minutes (with about 20 minutes of hands-on time), it has several drawback: it is expensive without subsidies (in Brazil, US$30 after subsidies, and US$180 without subsidies) [42], each cartridge processes only one sample, and the system is not suitable for areas with limited infrastructure. In contrast, the portable platform would cost around US$40 without subsidies, it does not consume all sample’s volume thus allowing retesting, it might be used in limited infrastructure situations, it processes two samples per run and provides results in up to 4 hours (about 20-25 minutes of hands-on time). Additionally, preliminary data show that the portable platform might be transported to remote health units or regions where the only available infrastructure is electricity and a roof, thus aiding in the screening of suspected TB cases and effectively helping to contain the spread of the disease in local communities.

6. I would recommend address more in details the trace results and elaborate more on the comparison/correlation of trace results vs FTA + Q3 plus.

Reply:

7. In remote areas, it is usually the case that the level of competency of laboratory technicians is more limited. I suggest to mention how feasible it would be to implement this technology especially around the results interpretation, is there any language barrier to read the results,.

Reply: At the current stage of development (validation of a prototype), we have not yet dealt with language barriers during implementation of the test. However, we do expect that a user friendly interface is created before the product launch in the market. This information is included in lines 498 -505.

8. Please elaborate on the easiness for operating and what it really means for the laboratory technician if s/he were to use this technology. You mention it takes up to 4 hours using Q3-plus. I guess you are also including the extraction steps in those 4 hours, please specify in your text. Also please add details on how long the lab technician needs to have hands-on for samples handling and processing. For example for GeneXpert it could around 20 minutes hands-on (adding buffer, mixing for 10 + 5 minutes, load the sample in the cartridge, launch the test). Please indicate out of the 4 hours, how long is required for actual hands-on.

Reply: The simplified protocol requires less than 30 minutes of hands-on time per 4-hour run. Our preliminary data shows that the simple steps of our portable protocol are easily performed by minimally trained technicians, which is the intended public for using it. This information is stated in lines 137-149/ 164-177/ 492 and 493.

9. Please add some details on what it implies for the health system to end up with false negative and/or false positive results.

Reply: The implications of false positive/negative results to the health system is stated in lines 477-485.

10. Please elaborate on the testing capacity of Xpert vs FTA+Q3-plus. How many samples can be tested in one run of 4 hours?

Reply: Both instruments have similar capacities. Two samples can be tested in one run of 4 hours in the FTA-Q platform, while one sample can be analyzed per Xpert cartridge. However, the Ultra system can run up to 4 cartridges, while the Q3 software can command up to 6 instruments, where each instrument would run two samples per 4-hour turn. This information is stated in lines 486-497.

Reviewer #2:

1. How affordable the assay will be as POC?

Reply: The simplified extraction protocol is very cheap (around US$ 1-2 per sample). The portable qPCR reagents, especially the silicon chip, are expensive (around US 30 per sample). This is one of the main reasons why we suggest that the portable platform (DNA extraction + qPCR) should be used in specific activities, geared towards high prevalence populations in remote or low-resource areas (lines 486-488).

2. Have you compared the sensitivity, specificity of the children's specimens? Do you think this can be different?

Reply: We have not compared the sensitivity and specificity of the simplified protocol with children´s samples. This information is not state in lines 106. However, we do not anticipate any differences between adult and children’s samples besides those already described in the literature, i.e., lower sensitivity due to the difficulty in obtaining a good sample from infant patients.

3. Why only adults specimens had been chosen?

Reply: The main reason was due to the easiness of collection, since children often are not able to produce a sputum sample.

Attachments
Attachment
Submitted filename: Point by point reply to Reviewers_Aug2024 (1).docx
Decision Letter - Shahriar Ahmed, Editor

Laboratory validation of a simplified DNA extraction protocol followed by a portable qPCR detection of M. tuberculosis DNA suitable for point of care settings.

PONE-D-24-12276R1

Dear Dr. Costa,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Shahriar Ahmed, MBBS, MHE, MPhil

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Thank you for submitting a revised version addressing all the comments from reviewers comprehensively. I would like to take this opportunity to congratulate all the authors. Thank you for submitting your manuscript to our journal and we look forward to working with you again in future.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Many thanks for all the adjustments. All concerns were addressed.

Reviewer #2: Thank you for addressing and incorporating all the responses in the manuscript. This looks good now for going forward for publication.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Dr Vibol IEM

Reviewer #2: No

**********

Formally Accepted
Acceptance Letter - Shahriar Ahmed, Editor

PONE-D-24-12276R1

PLOS ONE

Dear Dr. Costa,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Shahriar Ahmed

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .